MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
common stock, warrants...
$4,999K
Net cash provided by
financing activities
$4,273K
Canceled cashflow
$726K
Net (decrease)
increase in cash, cash...
-$24,684K
Canceled cashflow
$4,273K
Operating lease
right-of-use assets
-$3,132K
Stock-based compensation
$2,335K
Prepaid expenses and
other current assets
-$2,069K
Depreciation expense
$459K
Proceeds from the sale of
property and equipment
$18K
Payment of deferred
offering costs
$726K
Net cash used in
operating activities
-$28,859K
Canceled cashflow
$7,995K
Net cash (used in)
provided by investing...
-$98K
Canceled cashflow
$18K
Net loss
-$28,919K
Operating lease
liabilities
-$4,121K
Accrued expenses and
other current...
-$1,811K
Restructuring liability
-$1,081K
Accounts payable
-$516K
Deferred revenue
-$398K
Gain on sale of
property and equipment
$8K
Purchases of property and
equipment
$116K
Back
Back
Cash Flow
source: myfinsight.com
Lyra Therapeutics, Inc. (LYRA)
Lyra Therapeutics, Inc. (LYRA)